MX2023001483A - Compuestos inmunogenicos. - Google Patents

Compuestos inmunogenicos.

Info

Publication number
MX2023001483A
MX2023001483A MX2023001483A MX2023001483A MX2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A
Authority
MX
Mexico
Prior art keywords
sub
defined above
present
immunogenic compounds
peptide
Prior art date
Application number
MX2023001483A
Other languages
English (en)
Spanish (es)
Inventor
Gergana Galabova
Günther Staffler
Dorian Winter
Eva Mihailovska
Petra Gruber
Katja Balazs
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2023001483A publication Critical patent/MX2023001483A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2023001483A 2020-08-04 2021-08-04 Compuestos inmunogenicos. MX2023001483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189425 2020-08-04
PCT/EP2021/071778 WO2022029181A1 (en) 2020-08-04 2021-08-04 Immunogenic compounds

Publications (1)

Publication Number Publication Date
MX2023001483A true MX2023001483A (es) 2023-03-08

Family

ID=72178339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001483A MX2023001483A (es) 2020-08-04 2021-08-04 Compuestos inmunogenicos.

Country Status (10)

Country Link
US (1) US20230287050A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192493A1 (cg-RX-API-DMAC7.html)
JP (1) JP7898188B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230044524A (cg-RX-API-DMAC7.html)
CN (1) CN116261464A (cg-RX-API-DMAC7.html)
AU (1) AU2021322080A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185563A1 (cg-RX-API-DMAC7.html)
IL (1) IL300364A (cg-RX-API-DMAC7.html)
MX (1) MX2023001483A (cg-RX-API-DMAC7.html)
WO (1) WO2022029181A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314865A (en) * 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
KR20250135293A (ko) 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PL2723379T3 (pl) * 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスUnited Neuroscience シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN116261464A (zh) 2023-06-13
JP7898188B2 (ja) 2026-07-31
IL300364A (en) 2023-04-01
US20230287050A1 (en) 2023-09-14
WO2022029181A1 (en) 2022-02-10
CA3185563A1 (en) 2022-02-10
AU2021322080A1 (en) 2023-02-23
KR20230044524A (ko) 2023-04-04
EP4192493A1 (en) 2023-06-14
JP2023536497A (ja) 2023-08-25

Similar Documents

Publication Publication Date Title
Toniolo et al. Intramolecularly hydrogen-bonded peptide conformation
Geisler et al. Purification of smooth‐muscle desmin and a protein‐chemical comparison of desmins from chicken gizzard and hog stomach
Fukase et al. Total synthesis of peptide antibiotic nisin
US3929758A (en) Cyclization of cysteine-containing peptides
MX2023005770A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
US9206222B2 (en) Solid phase peptide synthesis of peptide alcohols
EP0366777A4 (en) Stimulation of chemotaxis by chemotactic peptides
IL152625A (en) Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits
ES2044841T3 (es) Procedimiento de preparacion de peptidos sinteticos con actividad de interleuquin 1 humana.
KR850007801A (ko) 폴리펩타이드의 제조방법
RU2003107100A (ru) Модифицированный фактор viii
CA2155004A1 (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
ATE527364T1 (de) Polypeptide erhaltend eine modifizierte menschliche serum-albumin sekretions-pre-sequenz mit erhöhtem ausscheidungsertrag
CL2024002370A1 (es) Vacunas terapeuticas anti-alfa-sinucleína.
US9598714B2 (en) Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents
ZA200604772B (en) Production of diphtheria toxin
Kawakami et al. Synthesis of Cysteine-Containing Polypeptide Using a Peptide Thioester Containing a Cys (Acm) Residue.
Hirano et al. Racemization of amino acid residues in proteins during roasting
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
IL312731A (en) Relaxin-2 fusion protein analogs and methods of using same
RU2004104335A (ru) Биологически активные пептиды
US20180215784A1 (en) Method for preparation of n-acyl peptides, polypeptides and proteins
ES2072422T3 (es) Procedimiento para la produccion de peptidos amidados en alfa en el terminal c.
Chiou et al. Biochemical comparison of γ-crystallins from duck and frog eye lenses
Goodman et al. Pyrrolidonecarboxylic acid at the N-terminal positions of polypeptide chains from leopard shark immunoglobulins